- Home
- RIGL vs FLYX Comparison
RIGL vs FLYX Comparison
Compare RIGL & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- FLYX
- Stock Information
- Founded
- RIGL 1996
- FLYX 2015
- Country
- RIGL United States
- FLYX United States
- Employees
- RIGL N/A
- FLYX N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- FLYX Blank Checks
- Sector
- RIGL Health Care
- FLYX Finance
- Exchange
- RIGL Nasdaq
- FLYX Nasdaq
- Market Cap
- RIGL 298.0M
- FLYX 264.1M
- IPO Year
- RIGL 2000
- FLYX N/A
- Fundamental
- Price
- RIGL $17.28
- FLYX $3.10
- Analyst Decision
- RIGL Buy
- FLYX
- Analyst Count
- RIGL 5
- FLYX 0
- Target Price
- RIGL $36.80
- FLYX N/A
- AVG Volume (30 Days)
- RIGL 222.1K
- FLYX 8.9K
- Earning Date
- RIGL 05-06-2025
- FLYX 01-01-0001
- Dividend Yield
- RIGL N/A
- FLYX N/A
- EPS Growth
- RIGL N/A
- FLYX N/A
- EPS
- RIGL 0.99
- FLYX N/A
- Revenue
- RIGL $179,278,000.00
- FLYX $327,274,000.00
- Revenue This Year
- RIGL $12.53
- FLYX $35.08
- Revenue Next Year
- RIGL $15.68
- FLYX N/A
- P/E Ratio
- RIGL $17.36
- FLYX N/A
- Revenue Growth
- RIGL 54.71
- FLYX 3.78
- 52 Week Low
- RIGL $7.48
- FLYX $1.79
- 52 Week High
- RIGL $29.82
- FLYX $8.39
- Technical
- Relative Strength Index (RSI)
- RIGL 44.84
- FLYX 49.99
- Support Level
- RIGL $16.05
- FLYX $2.95
- Resistance Level
- RIGL $17.52
- FLYX $3.19
- Average True Range (ATR)
- RIGL 1.26
- FLYX 0.18
- MACD
- RIGL 0.10
- FLYX 0.01
- Stochastic Oscillator
- RIGL 63.57
- FLYX 57.58
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 90 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.